Private Equity Bridgepoint Group Acquires Obagi Medical

Obagi Medical Sale to Bridgepoint Signals Growing Private Equity Interest in Medical Aesthetics

Private equity firm Bridgepoint has agreed to acquire Obagi Medical in a deal valued at up to $460 million, underscoring continued investor confidence in physician-dispensed skincare and the expanding convergence between medical aesthetics and professional beauty.

Bridgepoint will acquire 100% of Obagi Medical, a 38-year-old brand founded by dermatologist Zein Obagi and long positioned within the physician-dispensed skincare channel. The sale price includes cash, vendor notes, and potential earnout payments tied to future performance, bringing the total value to as much as $460 million.

Waldencast reportedly plans to use proceeds from the sale to pay down approximately $178 million in senior secured debt and concentrate future investment on Milk Makeup.

Leadership continuity after PE transition

Waldencast founders Michel Brousset and Hind Sebti are expected to leave the parent company at closing and transition to leadership roles at Obagi Medical in partnership with Bridgepoint. 

The founders shared their vision in a statement: “We will focus on the next chapter for Obagi Medical alongside Bridgepoint, a partner that share our long-term ambition for the brand: to build the number one dermatological mega-brand uniquely positioned to serve the beauty and wellness needs of physicians, patients and consumers worldwide.”

In a release, Waldencast board chairman Felipe Dutra said the board “believes this transaction represents the best path forward for Waldencast and its shareholders,“ strengthening the company’s balance sheet and allowing for a stronger focus on Milk Makeup.

Obagi’s evolution beyond topical skincare

Once known primarily for prescription-strength topical products, Obagi Medical has expanded significantly in recent years. In 2025, the company acquired Novaestiq, an aesthetics-focused business that paved the way for Obagi’s entry into aesthetic injectables. That acquisition led to the launch of the FDA-approved Obagi Saypha MagIQ dermal filler line in early 2026, positioning Obagi as a brand spanning both skincare and aesthetic treatments. 

The transaction is expected to close in the third quarter of 2026, pending customary regulatory approvals.